The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies

Diwei Zheng, Xindong Wang, Lin Cheng, Le Qin, Zhiwu Jiang, Ruocong Zhao, Yao Li, Jingxuan Shi, Qiting Wu, Youguo Long, Suna Wang, Zhaoyang Tang, Wei Wei, Jie Yang, Yangqiu Li, Hongsheng Zhou, Qifa Liu, Pentao Liu, Xinwen Chen, Yao Yao, Li-Hua Yang, Peng LiFrontiers in Immunology 2022 · DOI

TL;DR

This paper identifies the chemokine receptor CCR8 as a promising new target for CAR T-cell therapy in T-cell malignancies, particularly Adult T-cell Leukemia/Lymphoma (ATLL). The researchers demonstrate that CAR T-cells engineered to target CCR8 effectively kill ATLL and other T-ALL cells in vitro and in vivo without compromising T-cell expansion, offering a novel therapeutic avenue for these challenging cancers.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of B-cell leukemias and lymphomas, achieving remarkable success. However, its application to T-cell malignancies, such as ATLL and T-cell Acute Lymphoblastic Leukemia (T-ALL), faces significant hurdles. These include the scarcity of unique tumor antigens that are consistently expressed on T-cell cancers, the potential for T-cells to lose expression of target antigens leading to relapse, limitations in T-cell expansion, and the reliance on third-party donors or complex genome editing. The authors sought to identify novel, reliable targets for CAR T-cell therapy that could overcome these limitations and improve treatment outcomes for patients with T-cell malignancies.

Methods

The study employed a multi-pronged approach:

  • Bioinformatics Analysis: Publicly available gene expression datasets (GSE33615) were analyzed to compare CCR8 and CD7 expression levels in ATLL patients versus normal CD4 T cells.
  • Cell Line Characterization: ATLL cell lines (MT-4, C8166) and T-ALL cell lines (Jurkat, Molt-4) were analyzed for CCR8 and CD7 expression using flow cytometry.
  • CAR T-cell Construction and Production: Third-generation CAR constructs targeting CCR8 (using two different single-chain variable fragments, scFvs: 10A11 and 19D7) and CD19 (as a control) were designed. These constructs incorporated CD28, TLR2, and CD3ζ signaling domains. Lentiviral vectors were used to transduce primary human T cells.
  • In Vitro Assays:
    • T-cell Expansion and CAR Expression: Transduced T cells were cultured to assess their expansion rate and CAR expression levels over time.
  • Cytotoxicity Assays: The ability of anti-CCR8 CAR T cells to kill ATLL and T-ALL target cells was evaluated using luciferase-based assays.
  • Cytokine Release Assays: The production of key cytotoxic cytokines (Granzyme-B, IFN-γ) and degranulation marker (CD107a) by CAR T cells upon encountering target cells was measured using ELISA and flow cytometry, respectively.
  • In Vivo Experiments:
    • Xenograft Models: Immunodeficient NSI mice were inoculated with luciferase-labeled ATLL (MT-4-GL) or T-ALL (Jurkat-GL) cells.
  • Treatment and Monitoring: Mice were treated with anti-CCR8 CAR T cells or control CAR T cells. Tumor progression was monitored using bioluminescence imaging (BLI), and animal survival was tracked.

Datasets

  • GSE33615: A publicly available gene expression dataset from the GEO database used to analyze CCR8 and CD7 expression in ATLL patients and normal CD4 T cells.
  • GEPIA database: Used to assess CCR8 expression in human normal tissues.

Key Insights and Ideas

  • CCR8 as a Novel Target: The study strongly suggests that CCR8 is a highly relevant and potentially unique target for T-cell malignancies, particularly ATLL, as it is significantly upregulated in ATLL patients and cell lines while largely absent in normal T cells.
  • CD7 Limitations: The finding that ATLL cells do not express CD7 highlights the limitations of existing anti-CD7 CAR T-cell therapies for this specific patient population.
  • Safety and Efficacy of Anti-CCR8 CAR T Cells: Crucially, anti-CCR8 CAR T cells demonstrated potent antitumor activity in vitro and in vivo without negatively impacting T-cell expansion, a key concern for CAR T-cell therapies.
  • Mechanism of Action: The enhanced production of cytotoxic cytokines (Granzyme-B, IFN-γ) and degranulation marker (CD107a) by anti-CCR8 CAR T cells provides insight into their potent killing mechanisms.
  • Potential for Combination Therapy: The discussion hints at the possibility of dual CAR T-cell strategies (e.g., anti-CCR8 and anti-CD7, or anti-CCR8 and anti-MSLN) to further enhance efficacy and prevent antigen escape, especially in solid tumors.

Key Results

  • CCR8 Overexpression: ATLL patients and ATLL cell lines exhibited significantly higher CCR8 expression compared to normal CD4 T cells. Conversely, CD7 expression was lower in ATLL.
  • No Impairment of T-cell Expansion: Anti-CCR8 CAR T cells showed comparable expansion rates and CAR expression to control CAR T cells in vitro.
  • Potent In Vitro Cytotoxicity: Anti-CCR8 CAR T cells (both C1028z and C1928z variants) demonstrated significant killing of ATLL cell lines (MT-4, C8166) and CCR8-expressing T-ALL cells (Jurkat) in vitro.
  • Enhanced Cytokine Production: Anti-CCR8 CAR T cells produced higher levels of Granzyme-B and IFN-γ, and showed increased CD107a expression upon encountering target cells.
  • Effective In Vivo Tumor Suppression: In mouse models, anti-CCR8 CAR T cells significantly suppressed tumor growth and prolonged survival in mice bearing ATLL (MT-4-GL) and T-ALL (Jurkat-GL) tumors.
  • TAX Induction of CCR8: Expression of the oncogene TAX in T cells led to increased CCR8 expression, further supporting CCR8's relevance in ATLL pathogenesis.

Limitations and Future Work

  • Limited Scope of T-ALL Targets: While anti-CCR8 CAR T cells were effective against Jurkat cells, they did not suppress Molt-4 cells, indicating that CCR8 expression is not universal across all T-ALL subtypes. This suggests the need for careful patient selection or combination therapies.
  • Mouse Models: The experiments were conducted in immunodeficient mouse models. Future work should validate these findings in immunocompetent models or humanized mouse models to better reflect the human immune response.
  • Combination Therapies: The authors suggest that dual CAR T-cell strategies, such as combining anti-CCR8 with other targets (e.g., CD7 or MSLN), could be beneficial for preventing antigen escape and enhancing efficacy, particularly in solid tumors.
  • Clinical Translation: While promising, further preclinical development and clinical trials are necessary to confirm the safety and efficacy of anti-CCR8 CAR T-cell therapy in human patients.

Summary updated

Abstract

Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still have many challenges in their use for treating T cell malignancies, such as the lack of unique tumor antigens, their limitation of T cell expansion, and the need for third party donors or genome editing. Therefore, we need to find novel targets for CAR T cell therapy to overcome these challenges. Here, we found that both adult T-cell leukemia/lymphoma (ATLL) patients and ATLL cells had increased CCR8 expression but did not express CD7. Moreover, targeting CCR8 in T cells did not impair T cell expansion <i>in vitro</i>. Importantly, anti-CCR8 CAR T cells exhibited antitumor effects on ATLL- and other CCR8-expressing T-ALL cells <i>in vitro</i> and <i>in vivo</i>, and prolonged the survival of ATLL and Jurkat tumor-bearing mouse models. In conclusion, these collective results show that anti-CCR8 CAR T cells possess strong antitumor activity and represent a promising therapeutic approach for ATLL and CCR8<sup>+</sup> tumors.
BibTeX
@inproceedings{zheng2022chemokine,
  author = {Diwei Zheng and Xindong Wang and Lin Cheng and Le Qin and Zhiwu Jiang and Ruocong Zhao and Yao Li and Jingxuan Shi and Qiting Wu and Youguo Long and Suna Wang and Zhaoyang Tang and Wei Wei and Jie Yang and Yangqiu Li and Hongsheng Zhou and Qifa Liu and Pentao Liu and Xinwen Chen and Yao Yao and Li-Hua Yang and Peng Li},
  title = {{The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.808347},
}
Figure